Skip to content

Teva Pharma Belgium

Active
Public limited companyfounded 1994active for 32 yearsSneeuwbeslaan 20, 2610 Antwerpen, Belgium48 active companies are registered at this addressKBO/BCE: BE 0451.951.110

From the official registers: KBO 33 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

Teva Pharma Belgium has been active since 1994 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €6.7m and a net result of €2.2m. Equity is shrinking by about 14% per year across the filed financial years. Its solvency ranks better than 22% of 6,158 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.8% (low).

Risk analysisFollow ReportCompare
Teva Pharma BelgiumActiveChecked score 67/100
Risk analysis ReportCompare

Overview

Official details

KBO
Status
Active since 03-02-1994 Normal situation
Legal form
Public limited company
Registered office
Sneeuwbeslaan 20, 2610 Antwerpen
Activity
Wholesale of pharmaceutical and medical goods NACE 46460and 3 others
Establishment units
2.066.030.021 2610 Antwerpen, since 21-03-1994
2.251.284.183 2610 Antwerpen, since 01-01-2016
Financial year end
31 December
Peppol
Reachable since 08-12-2025
Company details

Who decides

Board
Auditor
RSM INTERAUDIT
Shareholders
Board & ownership

How it is doing

67 Healthy Checked score 2025
Bankruptcy probabilitywithin 12 months
0.8%
Annual accounts 2025
Turnover
€81.8m
▲ 8.9%
Profit
€2.2m
▲ 33.1%
Equity
€6.7m
▲ 48.3%
Total assets
€33.4m
▲ 34.0%
Staff
32.5 FTE
▲ 3.5%
2025 accounts 59 days early
Filed on 02-06-2026PDF
Financials
Why 67raises riskLiquidity: current ratio 1.24, cash €2781 change of registered office in 24 monthsEquity €6.7m (20.0% of total assets)lowers riskSize: turnover €81.8m, 32.5 FTE, total assets €33.4mShow the evidence

Checked score

Score 2025
67 / 100
Healthy
Probability in this band: 0.55% to 1.5%
Financially better than 40% of its sector peers (NACE 46, small)
Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Weak
Solvency 45+2
equity 20.0% of total assets
Liquidity 6+1
short-term debt 80.0% · cash 0.0%
Profitability 63+2
return on assets 6.5%
Bankruptcy probability, 12 months
0.8% Low
0%0.5%1.5%4%10%≥ 25%

About 8 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (4,376 companies, NACE 46, small)
Last 24 months 11-2024: 0.8% 12-2024: 0.8%● unchanged vs 11-2024 01-2025: 0.8%● unchanged vs 12-2024 02-2025: 0.7%▼ -0.1 percentage points vs 01-2025 03-2025: 0.7%● unchanged vs 02-2025 04-2025: 0.7%● unchanged vs 03-2025 05-2025: 0.7%● unchanged vs 04-2025 06-2025: 0.7%● unchanged vs 05-2025 07-2025: 0.9%▲ +0.2 percentage points vs 06-2025highest value 08-2025: 0.9%● unchanged vs 07-2025highest value 09-2025: 0.9%● unchanged vs 08-2025highest value 10-2025: 0.9%● unchanged vs 09-2025highest value 11-2025: 0.9%● unchanged vs 10-2025highest value 12-2025: 0.9%● unchanged vs 11-2025highest value 01-2026: 0.9%● unchanged vs 12-2025highest value 02-2026: 0.8%▼ -0.1 percentage points vs 01-2026 03-2026: 0.8%● unchanged vs 02-2026 04-2026: 0.8%● unchanged vs 03-2026 05-2026: 0.8%● unchanged vs 04-2026 06-2026: 0.8%● unchanged vs 05-2026 07-2026: 0.4%▼ -0.4 percentage points vs 06-2026lowest value 08-2026: 0.8%▲ +0.4 percentage points vs 07-2026 09-2026: 0.8%● unchanged vs 08-2026 10-2026: 0.8%● unchanged vs 09-2026
Credit of up to €440,000 on 30-day terms is acceptable
Liquidity tight (current ratio 1.24, compared with 1.21 in 2024, below the usual 1.5; short-term debt: 80% and cash: 0% of total assets), and 80% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small): better than 22% on solvency, 6% on liquidity, 50% on profitability and 84% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Seven signals.
lowers riskraises riskneutral
raises risk · Liquidity: current ratio 1.24, cash €278
NBB · annual accounts
raises risk · 1 change of registered office in 24 months
Belgian Official Gazette
raises risk · Equity €6.7m (20.0% of total assets)
NBB · annual accounts
lowers risk · Size: turnover €81.8m, 32.5 FTE, total assets €33.4m
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 22% of 6158 sector peers (2025).
NBB · sector comparison
Position among 6158 sector peers
Solvency
better than 22%
← weakest strongest →
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025
Equity per financial year
1819202122232425
2018 to 2025 · latest year €6.7m
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 02-06-2026, 59 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
59 days early
2024
58 days early
2023
2 days early
2022
98 days late
2021
61 days early
2020
45 days early
2019
76 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 7 days before the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 3 June (4 of the last 5 filed years within 57 days of that day).
Companies Code · seven months
Where today falls in the filing period
01-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage

Key points

  • Positive: Among the best 10% on net resultsector median €112,134 · 6,092 companies €2.2m View
  • Positive: 8 profitable years in a rowprofit 2025: €2.2m 8 years View
  • Positive: Equity rose in 2025from €4.5m to €6.7m ▲ 48.3% View

Documents

Annual accounts at the NBB

All 33 annual accounts

Acts in the Belgian Official Gazette

All publications in the Belgian Official Gazette

Articles and registers

Key facts about Teva Pharma Belgium

What is the company number of Teva Pharma Belgium?
0451.951.110. In Belgium the VAT number is the company number with BE in front: BE 0451.951.110.
Where is Teva Pharma Belgium based?
The registered office is at Sneeuwbeslaan 20, 2610 Antwerpen.Company details
What does Teva Pharma Belgium do?
According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
What is the legal form of Teva Pharma Belgium?
Public limited company (NV).
When was Teva Pharma Belgium founded?
On 03-02-1994.
Is Teva Pharma Belgium still active?
Yes, Teva Pharma Belgium is an active enterprise in the KBO register.
How many employees does Teva Pharma Belgium have?
On average 32.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of Teva Pharma Belgium?
€81.8m in financial year 2025, according to the filed annual accounts.
Is Teva Pharma Belgium profitable?
In financial year 2025, Teva Pharma Belgium made a profit of €2.2m.
Where can I find the annual accounts of Teva Pharma Belgium?
Teva Pharma Belgium filed 33 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts 2025 (PDF)
When are the next annual accounts of Teva Pharma Belgium due?
By 31-07-2027, for financial year 2026.Timeline

Companies related to Teva Pharma Belgium

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure